A recent analysis has revealed that the cost of the biologic medicine Stelara, used to treat autoimmune diseases, is significantly higher for Medicare and its beneficiaries when obtained at pharmacies compared to when administered in physician offices. The drug, manufactured by Johnson & Johnson, is approved to treat conditions such as psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. However, Medicare spending on Stelara has seen a substantial increase from $300 million in 2016 to nearly $3 billion in 2023, according to a report by the Office of Inspector General of the Department for Health and Human Services.
The spike in costs has been attributed to the Medicare Part D program, where beneficiaries purchase their medications from pharmacies. Over a seven-year period, the average cost of a Stelara injection through Part D rose from $17,700 to $32,500, marking an 84% increase. In contrast, the cost of the drug through the Part B program, where doctors administer injections in their offices, decreased from $14,450 to almost $13,000 during the same period.
The disparity in costs between Part D and Part B raises concerns about the affordability and accessibility of essential medications for Medicare beneficiaries. It highlights the importance of examining payment mechanisms and reimbursement structures to ensure that patients can access necessary treatments without facing exorbitant costs.
Moreover, the analysis underscores the need for greater transparency and oversight in drug pricing and reimbursement practices within the Medicare program. As the cost of specialty medications like Stelara continues to rise, policymakers and healthcare stakeholders must work together to address these challenges and develop sustainable solutions that balance cost-effectiveness with quality care for patients.
In conclusion, the findings of the analysis shed light on the complex dynamics of Medicare drug pricing and the impact on both the program and its beneficiaries. By exploring alternative payment models and promoting greater accountability in the pharmaceutical industry, we can strive to create a healthcare system that prioritizes affordability, accessibility, and patient-centered care.
